Choline PET/CT and MRI for Targeted Prostate Biopsy

This is an explorative diagnostic basic research study to assess the value of 18F-choline
PET/CT and multi-sequence MRI for prostate cancer in patients undergoing diagnostic prostate
biopsy. Patients will receive image-guided (targeted) prostate biopsies and metabolomic
profiling of prostate biopsy tissues to evaluate underlying metabolic changes in comparison
with pathological Gleason grading.

Inclusion Criteria:

- Males 40 years of age or older scheduled for prostate biopsy (for known or suspected
prostate cancer) followed by planned prostatectomy (population group A)

- Males 40 years of age or older with known (biopsy‐confirmed) primary adenocarcinoma of
the prostate undergoing active surveillance scheduled for prostate biopsy (population
group B)

Exclusion Criteria:

- Androgen ablation (hormone treatment) within the last 3 months

- Prostate biopsy within 6 weeks prior to PET or MRI imaging

- Active inflammatory bowel disease within the last 6 months

- Acute prostatitis within the last 6 months

- A non‐urologic bacterial infection requiring active treatment with antibiotics

- Active other malignancy (except basal cell or squamous cell skin cancer) within the
last 2 years

- Previous radiation treatment of the pelvis

- Symptomatic distal rectal stenosis

- Known hypersensitivity to glucagon

- Pheochromocytoma, insulinoma or galactosemia

- Insulin‐dependent diabetes